Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...
The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.
Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.
Shares of Moderna dropped more than 20% intraday to $33.44, more than erasing gains last week after the first bird-flu death ...
Moderna's shares plummeted after cutting its revenue guidance for 2025 due to slow demand for Covid and RSV vaccines.
The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...
In a report released today, Tim Anderson from Bank of America Securities maintained a Sell rating on Moderna (MRNA – Research Report), with a ...
Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback